<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177693</url>
  </required_header>
  <id_info>
    <org_study_id>PREFRIEND</org_study_id>
    <nct_id>NCT04177693</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Hepatic Safety of EGCG</brief_title>
  <official_title>Pharmacokinetics and Hepatic Safety of EGCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial to assess the pharmacokinetics and hepatic safety of EGCG in women with and without
      uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, multi-center, pharmacokinetics and hepatic safety trial of EGCG
      with 36 total patients in 3 treatment arms. 36 women will be randomized to one of the
      following groups: EGCG daily alone, EGCG daily with clomiphene citrate and EGCG daily with
      letrozole. The randomization scheme will be stratified for age groups 18-29 and 30-40 and
      presence of uterine fibroids. The pharmacokinetics and hepatic safety of EGCG with clomiphene
      citrate and letrozole are unknown. The trial conducted in women with and without fibroids
      will allow comparisons between these groups. The results of this study will be used to
      confirm hepatic safety for the larger multi-center FRIEND study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The 36 women will be randomized to one of the following groups:
EGCG daily alone.
EGCG daily with clomiphene citrate 100mg for 5 days.
EGCG daily with letrozole 5mg for 5 days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in epigallocatechin gallate (EGCG)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Differences in epigallocatechin gallate (EGCG) between the 3 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in epigallocatechin (EGC)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Differences in epigallocatechin (EGC) between the 3 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in epicatechin gallate(ECG)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Differences in epicatechin gallate(ECG) between the 3 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 4'-O-methyl-epigallocatechin</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Differences in 4'-O-methyl-epigallocatechin between the 3 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in direct and total bilirubin</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in direct and total bilirubin between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT/AST</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in alanine aminotransferase /aspartate aminotransferase (ALT/AST) between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Alkaline Phosphatase</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in Alkaline Phosphatase between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in βhCG</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in beta human chorionic gonadotropin (βhCG) between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FSH</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in Follicle-stimulating hormone (FSH) between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LH</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in Luteinizing hormone (LH) between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Estrogen</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in Estrogen between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Progesterone</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in Progesterone between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AMH</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in anti-mullerian hormone (AMH) between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endometrial thickness</measure>
    <time_frame>Up to 55 days</time_frame>
    <description>Changes in endometrial thickness between the 3 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in epigallocatechin gallate (EGCG)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in epigallocatechin gallate (EGCG) within each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in epigallocatechin (EGC)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in epigallocatechin (EGC) within each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in epicatechin gallate(ECG)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in epicatechin gallate(ECG) within each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 4'-O-methyl-epigallocatechin</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Changes in 4'-O-methyl-epigallocatechin within each group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>EGCG daily alone.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGCG daily alone. 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGCG with clomiphene citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGCG 800 mg daily with clomiphene citrate 100mg for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGCG with letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGCG 800mg daily with letrozole 5mg for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Epigallocatechin gallate (EGCG)</intervention_name>
    <description>800 mg (2 capsules) of decaffeinated EGCG (green tea extract), taken orally on a daily basis for up to 2 months</description>
    <arm_group_label>EGCG daily alone.</arm_group_label>
    <arm_group_label>EGCG with clomiphene citrate</arm_group_label>
    <arm_group_label>EGCG with letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>100 mg for 5 days</description>
    <arm_group_label>EGCG with clomiphene citrate</arm_group_label>
    <other_name>Clomid</other_name>
    <other_name>Serophene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>5 mg for 5 days</description>
    <arm_group_label>EGCG with letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy women ≥18 to ≤40 years of age with or without uterine fibroids

          2. Must use a double-barrier method for contraception

        Exclusion Criteria:

          1. Subjects using green tea/EGCG within 2 weeks prior to study enrollment

          2. Known liver disease (defined as AST or ALT&gt;2 times normal, or total bilirubin &gt;2.5
             mg/dL).

          3. History of alcohol abuse (defined as &gt;14 drinks/week) or binge drinking of ≥ 6 drinks
             at one time).

          4. Subject using hormonal contraceptives

          5. Subjects who are pregnant or breastfeeding

          6. Known hypersensitivity to the study drugs

          7. Any chronic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman Al-Hendy, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Segars, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Taylor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heping Zhang, PhD</last_name>
    <phone>203-785-5185</phone>
    <email>heatherly.carlson@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heatherly Carlson, MA</last_name>
    <phone>203-737-4845</phone>
    <email>heatherly.carlson@yale.edu</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Epigallocatechin gallate</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

